Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...

Breast Cancer Foundation NZ is calling on Pharmac to widen access to Keytruda in light of new incontrovertible evidence that the treatment will save the lives of women with early-stage triple negative ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.